Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 14/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.61 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14330723 | 1.00 | FOLH1 (0.61) | FOLH1NAALAD2RIMKLASMN1; SMN2LMNA | |
| SCHEMBL13559298 | 0.91 | FOLH1 (0.59) | FOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL11936626 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLASMN1; SMN2LMNA | |
| SCHEMBL9965336 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLASMN1; SMN2LMNA | |
| SCHEMBL16580430 | 0.85 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLASMN1; SMN2LMNA | |
| SCHEMBL14549945 | 0.84 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLASMN1; SMN2 | |
| SCHEMBL11936652 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22636039 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14719987 | 0.83 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14331633 | 0.83 | FOLH1 (0.81) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-19 | — | — | US | disclosed |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | GEORGETOWN UNIVERSITY (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150079001-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885NAALAD2 3/4885RIMKLA 197/4885 |
| US-20120276007-A1 | IMAGING AGENTS AND METHODS OF IMAGING NAALADASE OR PSMA | FOLH1, DNPEP, NAALAD2 | FOLH1 1/4885NAALAD2 3/4885RIMKLA 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.